This Phase 1 dose-escalation trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ...
Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.
How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...
B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with ...
Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, demand for off-the-shelf immunotherapies, combination strategies, AI in patient ...
A pivotal trial of obinutuzumab has demonstrated the strongest evidence yet of the efficacy of B-cell depletion in systemic ...
The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...
Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results